| target_debate_target | Should CERS2 (Ceramide synthase 2) be prioritized as a therapeutic target for ne | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should NLGN1 (Neuroligin-1) be prioritized as a therapeutic target for neurodege | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CHMP2B (Charged multivesicular body protein 2B) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SREBF2 (Sterol regulatory element binding transcription factor 2) be prio | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SMPD1 (Sphingomyelin phosphodiesterase 1) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should NPM1 (Nucleophosmin) be prioritized as a therapeutic target for neurodege | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should TARDBP (TAR DNA-binding protein 43) be prioritized as a therapeutic targe | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CYP46A1 (Cytochrome P450 Family 46 Subfamily A Member 1) be prioritized a | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should OCLN (Occludin) be prioritized as a therapeutic target for neurodegenerat | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ZO1 (Zonula occludens-1) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should COX4I1 (Cytochrome C Oxidase Subunit 4I1) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should KDM6A (Lysine demethylase 6A) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should PLA2G4A (Phospholipase A2 group IVA) be prioritized as a therapeutic targ | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should MLCK (Myosin light chain kinase) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ABCB1 (P-glycoprotein) be prioritized as a therapeutic target for neurode | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should IGF2R (Insulin-like growth factor 2 receptor) be prioritized as a therape | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should PIEZO1 (Piezo-type mechanosensitive ion channel component 1) be prioritiz | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should DNAJB1 (DnaJ heat shock protein family (Hsp40) member B1) be prioritized | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_sda-2026-04-01- | This analysis aims to elucidate the mechanisms by which gut microbiome dysbiosis | 0.82 | 5 | 4 | completed | 2026-04-22 | sda-2026-04-01-gap-20260401-225155 |
| sess_SDA-2026-04-02- | What is the role of microglial synaptic pruning in Alzheimer's disease and other | 0.68 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| sess_SDA-2026-04-02- | Why are entorhinal cortex layer II neurons among the earliest and most selective | 0.78 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| target_debate_target | Should SST (Somatostatin) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should P2RY1ANDP2RX7 (P2RY1ANDP2RX7) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-02- | Which cell types show the greatest vulnerability in Alzheimer's disease accordin | 0.75 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-02-gap-seaad-debate-v4 |
| target_debate_target | Should DNASE2 (Deoxyribonuclease 2 lysosomal) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-02- | Analysis for knowledge gap 006 in the neurodegeneration domain. | 0.79 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-02-gap-2026-04-01-gap-006 |
| target_debate_target | Should IL10 (Interleukin-10) be prioritized as a therapeutic target for neurodeg | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should NTN1 (Netrin-1) be prioritized as a therapeutic target for neurodegenerat | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-02- | What mechanisms govern antibody transport across the blood-brain barrier and how | 0.82 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-02-gap-bbb-antibody-transport |
| target_debate_target | Should HCRT (Hypocretin/Orexin) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-02- | What are effective therapeutic strategies for targeting APOE4 in Alzheimer's dis | 0.82 | 4 | 4 | completed | 2026-04-22 | SDA-2026-04-02-gap-apoe4-targeting |
| target_debate_target | Should HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) be prioritized | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ALOX12 (12-lipoxygenase) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Investigate prion-like spreading of tau pathology through connected brain region | 0.73 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-20260404-052358 |
| target_debate_target | Should LAMP1 (Lysosomal associated membrane protein 1) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Epigenetic reprogramming of aging neurons represents an active research focus wi | 0.67 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-20260404-060512 |
| target_debate_target | Should AHR (Aryl hydrocarbon receptor) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should BMAL1 (Basic Helix-Loop-Helix ARNT Like 1) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | APOE4 is the strongest genetic risk factor for late-onset AD. How APOE4 specific | 0.78 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-apoe4-lipid-metabolism |
| target_debate_target | Should VCP (Valosin containing protein) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should NAMPT (Nicotinamide phosphoribosyltransferase) be prioritized as a therap | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Tau pathology spreads through synaptically connected brain regions in Alzheimer | 0.78 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-tau-prion-spreading |
| target_debate_target | Should CRH (Corticotropin Releasing Hormone) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should C1QA (Complement C1q A Chain) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Investigate mechanisms of epigenetic reprogramming in aging neurons | 0.79 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| target_debate_target | Should ALOX15 (15-lipoxygenase) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CLOCK (Circadian Locomotor Output Cycles Kaput) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Lysosomal membrane permeabilization releasing cathepsins triggers NLRP3 inflamma | 0.76 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-lysosomal-cathepsin-ad |
| target_debate_target | Should CMKLR1 (Chemokine-like Receptor 1) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-06- | The study establishes G3BP1's role as a tunable switch for stress granule assemb | 0.69 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |